6533b7d2fe1ef96bd125edc6
RESEARCH PRODUCT
Chronic Apical and Nonapical Right Ventricular Pacing in Patients with High-Grade Atrioventricular Block: Results of the Right Pace Study
Giovanni Luca BottoDaniele PorcelliAnna RagoSergio ValsecchiAlessandro CostaRaimondo CalvaneseMonica CampariMarco Tullio BarattoGiampiero MagliaDomenico PecoraCarmine MutoMassimo GiammariaValeria CalviGianfranco CiaramitaroRiccardo Airò FarullaSantina PatanèAlbino Reggianisubject
Genetics and Molecular Biology (all)Malemedicine.medical_specialtyArticle SubjectImmunology and Microbiology (all)Heart Ventricleslcsh:Medicine030204 cardiovascular system & hematologyBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicinemedicine80 and overHumansIn patientSingle-Blind Method030212 general & internal medicineInterventricular septumProspective StudiesAtrioventricular BlockAgedAged 80 and overGeneral Immunology and Microbiologybusiness.industrylcsh:RCardiac Pacing ArtificialReproducibility of ResultsAtrial fibrillationGeneral MedicineVentricular pacingmedicine.diseaseIncreased riskmedicine.anatomical_structureHigh grade atrioventricular blockTreatment OutcomeBaseline characteristicsHeart failureArtificialCardiologyClinical StudyQuality of LifeCardiac PacingFemalebusinessAged; Aged 80 and over; Female; Heart Ventricles; Humans; Male; Prospective Studies; Quality of Life; Reproducibility of Results; Single-Blind Method; Treatment Outcome; Atrioventricular Block; Cardiac Pacing Artificial; Biochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)description
Objective. The aim of the study was to compare the two approaches to chronic right ventricular pacing currently adopted in clinical practice: right ventricular apical (RVA) and non-RVA pacing. Background. Chronic RVA pacing is associated with an increased risk of atrial fibrillation, morbidity, and even mortality. Non-RVA pacing may yield more physiologic ventricular activation and provide potential long-term benefits and has recently been adopted as standard procedure at many implanting centers. Methods. The Right Pace study was a multicenter, prospective, single-blind, nonrandomized trial involving 437 patients indicated for dual-chamber pacemaker implantation with a high percentage of RV pacing. Results. RV lead-tip target location was the apex or the interventricular septum. RVA (274) and non-RVA patients (163) did not differ in baseline characteristics. During a median follow-up of 19 months (25th–75th percentiles, 13–25), 17 patients died. The rates of the primary outcome of death due to any cause or hospitalization for heart failure were comparable between the groups (log-rank test, p=0.609), as were the rates of the composite of death due to any cause, hospitalization for heart failure, or an increase in left ventricular end-systolic volume ≥ 15% as compared with the baseline evaluation (secondary outcome, p=0.703). After central adjudication of X-rays, comparison between adjudicated RVA (239 patients) and non-RVA (170 patients) confirmed the absence of difference in the rates of primary (p=0.402) and secondary (p=0.941) outcome. Conclusions. In patients with indications for dual-chamber pacemaker who require a high percentage of ventricular stimulation, RVA or non-RVA pacing resulted in comparable outcomes. This study is registered with ClinicalTrials.gov (identifier: NCT01647490).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-05-01 | BioMed Research International |